Step 1 topics → Hematology and Oncology → Hemoglobin C Disease

Hemoglobin C Disease

USMLE Step 1 trap: Underestimates severity of HbSC compound heterozygote relative to HbSS. HbSC compound heterozygotes have significant sickling disease (intermediate severity between HbSS and HbS trait) because HbC promotes HbS polymerization.

Hemoglobin C disease is a hemolytic anemia caused by a point mutation in the beta-globin gene — specifically a glutamate-to-lysine substitution at position 6. That's the same position as the HbS mutation, but a different amino acid swap, and that distinction is exactly the kind of detail USMLE Step 1 loves to test. The critical misconception to fix at the outset: because HbC is milder than HbS, students assume HbSC compound heterozygotes will have a nearly benign course — wrong. HbC actually promotes HbS polymerization, making HbSC disease a real sickling disorder with intermediate severity. HbC is low-yield overall, but when it shows up, it appears as a comparison or contrast question against HbS or a smear-interpretation question about target cells and crystals.

The trickiest part of this topic is the compound heterozygote HbSC. Students tend to reason that since HbC is milder than HbS, HbSC must be mild too. That reasoning is wrong and the exam will exploit it. HbC actually promotes HbS polymerization, so HbSC disease causes real sickling complications — it sits between HbSS and HbS trait in severity, not near the benign end. The second common trap is the smear: HbC does not produce sickle cells. It produces target cells and distinctive bar-shaped intracellular crystals, and the confirmatory test is hemoglobin electrophoresis, not anything visual.

On USMLE Step 1, this concept is most likely to appear in a clinical vignette describing a patient with mild hemolytic anemia and an unusual smear finding, or in a two-part question asking you to both identify the mutation and select the confirmatory test. Know the molecular distinction from HbS cold, and don't underestimate HbSC.

From real student decks
11%have cards covering this topic
0%have mature cards

A gap in most decks — fewer than half of students in our cohort have cards covering this topic.

Common misconceptions

Common mistake
Wrong: HbSC disease is as mild as HbCC because HbC is a milder mutation than HbS.
Right: HbSC compound heterozygotes have significant sickling disease (intermediate severity between HbSS and HbS trait) because HbC promotes HbS polymerization.
The logic 'HbC is milder, so HbSC is mild' sounds reasonable but ignores the biochemistry. HbC actually stabilizes or promotes the polymerization of HbS, meaning the two abnormal hemoglobins interact in a way that enables sickling. HbSC disease causes vaso-occlusive crises, retinal complications, and avascular necrosis — real clinical disease that's intermediate in severity between HbSS and HbS trait. Never equate compound heterozygosity with a benign course without knowing the specific interaction.
Common mistake
Wrong: HbC results from the same glutamate-to-valine substitution as HbS but at a different position.
Right: HbC results from a glutamate-to-lysine substitution at beta-globin position 6, whereas HbS is glutamate-to-valine at the same position.
Both HbS and HbC affect the same codon — position 6 of the beta-globin chain — but they are different mutations that produce different amino acid changes. HbS swaps glutamate for valine (acidic to nonpolar, which drives hydrophobic polymerization), while HbC swaps glutamate for lysine (acidic to basic). The different substitution explains why HbC forms crystals rather than polymers and causes a milder hemolytic anemia rather than vaso-occlusive disease.
Common mistake
Wrong: HbC disease produces sickle cells on peripheral smear similar to HbSS.
Right: HbC disease produces target cells and HbC crystals (bar-shaped intracellular inclusions) on smear, not sickle cells.
HbC does not polymerize the way HbS does, so it does not produce sickle-shaped cells. Instead, HbC crystallizes inside red blood cells, forming bar-shaped intracellular inclusions called HbC crystals. The increased membrane rigidity from these crystals and the associated dehydration produce the classic target cell appearance on smear. If you see sickle cells, think HbSS or HbSC — if you see crystals and target cells with no sickle forms, think HbCC.
Common mistake
Gap: Missing that hemoglobin electrophoresis is the confirmatory test for HbC disease
Hemoglobin electrophoresis is the confirmatory test for HbC disease, distinguishing HbC from HbS and other variants by migration pattern.
Peripheral smear findings like target cells and HbC crystals are suggestive but not diagnostic — you cannot definitively distinguish hemoglobin variants by morphology alone. Hemoglobin electrophoresis separates hemoglobin variants by charge and size, allowing you to confirm the presence of HbC and quantify its proportion relative to HbA and other variants. This is the same confirmatory test used for HbS, HbE, and other structurally abnormal hemoglobins, so it's a high-utility concept even in a low-yield topic.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Know that HbC results from a glutamate-to-lysine substitution (not glutamate-to-valine like HbS) at beta-globin position 6 — the exam distinguishes these at the amino acid level.
  2. Understand that HbSC compound heterozygotes have intermediate-severity sickling disease, not a mild course, because HbC promotes HbS polymerization.
  3. Recognize that HbC disease on peripheral smear shows target cells and bar-shaped HbC crystals — not sickle cells — and be able to distinguish this from HbSS smear findings.
  4. Know that hemoglobin electrophoresis is the confirmatory test for HbC disease, used to distinguish HbC from HbS and other hemoglobin variants by their migration pattern.

Can you avoid these mistakes?

A patient with mild hemolytic anemia has a peripheral smear showing numerous target cells and occasional bar-shaped intracellular inclusions. What is the most likely hemoglobin variant, and what test confirms it?
At the molecular level, how does the HbC mutation differ from the HbS mutation, and how does this difference explain why HbCC causes crystal formation rather than sickling?
A patient is found to be a compound heterozygote for HbS and HbC (HbSC). A classmate argues this patient will have a nearly benign course because HbC is a mild mutation. What is wrong with this reasoning, and what is the expected clinical severity of HbSC disease?
You are reviewing smears from three patients: one with HbSS, one with HbCC, and one with HbSC. Which smear finding is specific to HbCC and would NOT be expected in HbSS?

Related topics

Hemolytic Anemia — Intravascular vs Extravascular Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →